Answers are grounded in this paper and cite their sources.
This research demonstrates effective triagonist peptides for diabetes and obesity, highlighting potential therapeutic benefits.
Rational design and molecular modelling enabled the development of potent GLP-1/GIP/GCGR triagonists with robust in vitro activity and efficacy comparable to established incretin agonists.
No takes yet. Share an insight, caveat, or question.
Kalinowska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: